Erythrocytic or serum hydrogen sulfide association with hypertension development in untreated essential hypertension

Chinese Medical Journal

Volumn 124, Issue 22, 2011, Pages 3693-3701

  Zheng, Mei ^a   Zeng, Qiang ^b   Shi, Xiao Qin ^c   Zhao, Jing ^c,d   Tang, Chao Shu ^c,d   Sun, Ning Ling ^a   Geng, Bin ^c,d  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

3 mercaptopyruvate sulphurtransferase; Erythrocyte; Hydrogen sulfide; Hypertension

Indexed keywords

3 MERCAPTOPYRUVATE SULFURTRANSFERASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROGEN SULFIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFURTRANSFERASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY MASS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ERYTHROCYTE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ERYTHROCYTES; FEMALE; HUMANS; HYDROGEN SULFIDE; HYPERTENSION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 82255161914     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.22.017     Document Type: Article

References (32)

1. Kamoun P. Endogenous production of hydrogen sulfide in mammals. Amino Acids 2004; 26: 243-254.
2. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J 2001; 20: 6008-6016.
3. Geng B, Yang J, Qi Y, Zhao J, Pang Y, Du J, et al. H2S generated by heart in rat and its effects on cardiac function. Biochem Biophys Res Commun 2004; 313: 362-368.
4. Fang L, Zhao J, Chen Y, Ma T, Xu G, Tang C, et al. Hydrogen sulfide derived from periadventitial adipose tissue is a vasodilator. J Hypertens 2009; 27: 2174-2185.
5. Zhong G, Chen F, Cheng Y, Tang C, Du J. The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. J Hypertens 2003; 21: 1879-1885.
6. Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biophys Res Commun 2004; 313: 22-27.
7. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008; 322: 587-590.
8. Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, et al. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 2008; 117: 2351-2360.
9. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, et al. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid Redox Signal 2009; 11: 703-714.
10. Nagahara N, Ito T, Kitamura H, Nishino T. Tissue and subcellular distribution of mercaptopyruvate sulfurtransferase in the rat: confocal laser fluorescence and immunoelectron microscopic studies combined with biochemical analysis. Histochem Cell Biol 1998; 110: 243-250.
11. Martensson J, Sorbo B. Human beta-mercaptopyruvate sulfurtransferase: distribution in cellular compartments of blood and activity in erythrocytes from patients with hematological disorders. Clin Chim Acta 1978; 87: 11-15.
12. Williams RA, Kelly SM, Mottram JC, Coombs GH. 3-Mercaptopyruvate sulfurtransferase of Leishmania contains an unusual C-terminal extension and is involved in thioredoxin and antioxidant metabolism. J Biol Chem 2003; 278: 1480-1486.
13. Nagahara N, Ito T, Minami M. Mercaptopyruvate sulfurtransferase as a defense against cyanide toxication: molecular properties and mode of detoxification. Histol Histopathol 1999; 14: 1277-1286.
14. Zhao J, Fang LP, Xu GY, Tang CS, Geng B. Assay of endogenous hydrogen sulfide from erythrocytes. J Peking Univ (Health Sci) (Chin) 2007; 39: 449-452.
15. Valentine WN, Frankenfeld JK. 3-Mercaptopyruvate sulfurtransferase (EC 2.8.1.2): a simple assay adapted to human blood cells. Clin Chim Acta 1974; 51: 205-210.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
17. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142-161.
18. Olson KR. Is hydrogen sulfide a circulating "gasotransmitter" in vertebrate blood? Biochim Biophys Acta 2009; 1787: 856-863.
19. Shibuya N, Mikami Y, Kimura Y, Nagahara N, Kimura H. Vascular endothelium expresses 3-mercaptopyruvate sulfu-rtransferase and produces hydrogen sulfide. J Biochem 2009; 146: 623-626.
20. Frendo J, Wrobel M. The activity of 3-mercaptopyruvate sulfurtransferase in erythrocytes from patients with polycythemia vera. Acta Biochim Pol 1997; 44: 771-773.
21. Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal 2010; 12: 1-13.
22. Feng X, Chen Y, Zhao J, Tang C, Jiang Z, Geng B. Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator. Biochem Biophys Res Commun 2009; 380: 153-159.
23. Goonasekera CD, Shah V, Rees DD, Dillon MJ. Nitric oxide activity in childhood hypertension. Arch Dis Child 1997; 77: 11-16.
24. Higashino H, Miya H, Mukai H, Miya Y. Serum nitric oxide metabolite (NO(x) levels in hypertensive patients at rest: a comparison of age, gender, blood pressure and complications using normotensive controls. Clin Exp Pharmacol Physiol 2007; 34: 725-731.
25. Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
26. Geng B, Cui Y, Zhao J, Yu F, Zhu Y, Xu G, et al. Hydrogen sulfide downregulates the aortic L-arginine/nitric oxide pathway in rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1608-R1618.
27. Duprez DA. Systolic hypertension in the elderly: addressing an unmet need. Am J Med 2008; 121: 179-184 e3.
28. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603.
29. Wang Y, Zhao X, Jin H, Wei H, Li W, Bu D, et al. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2009; 29: 173-179.
30. Ogle JW, Lange RD, Dunn CD. Production of erythropoietin in vitro: a review. In Vitro 1978; 14: 945-950.
31. Hui Y, Du J, Tang C, Bin G, Jiang H. Changes in arterial hydrogen sulfide (H2S) content during septic shock and endotoxin shock in rats. J Infect 2003; 47: 155-160.
32. Li L, Hsu A, Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation--a tale of three gases! Pharmacol Ther 2009; 123: 386-400.